Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cogent Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Its core programs include bezuclastinib, a selective KIT inhibitor for systemic mastocytosis and gastrointestinal stromal tumors, and CGT4859, an FGFR2 inhibitor. The company aims to address unmet medical needs with targeted, innovative medicines for rare cancers and disorders, leveraging proprietary technology and strategic licensing.
This description was generated via AI from an annual report. Updated about 1 year ago.